• Cerenome completed enrollment in its Phase 2 ReSPECT-GBM trial of REYOBIQ for recurrent glioblastoma, with 32 patients treated versus 34 planned.
• A statistical review found the reduced enrollment sufficient for final analysis, with minimal impact on statistical power.
• Topline results are expected in mid-2027, followed by an FDA meeting to discuss the program’s next steps.
• Interim results showed median overall survival of 13 months in 15 patients versus approximately eight months historically reported for bevacizumab monotherapy.
• Across Phases 1 and 2, most treatment-related adverse events were mild or moderate; no treatment-related deaths occurred.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerenome Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290730PRIMZONEFULLFEED9855854) on October 29, 2026, and is solely responsible for the information contained therein.